Repligen has locked in its acquisition of BioLife Solutions, shaking up the field for cell and gene therapy manufacturing. The $1.5 billion deal brings together two players with different strengths: Repligen’s bioprocessing know-how and BioLife’s cell therapy tools.
An official SEC filing shows the transaction closed on October 6, 2026, after a two-step merger. BioLife Solutions is no longer a standalone public company. It now runs as a wholly owned Repligen subsidiary, later renamed BioLife Solutions, LLC.
Following the closing of the deal, BioLife Solutions' shares were delisted from Nasdaq and the company began the process of deregistering its securities and reporting obligations with the SEC.
With BioLife Solutions now part of Repligen, the company picks up a set of cell processing tools and biopreservation media already used widely in cell therapy manufacturing. Repligen says BioLife’s CryoStor product supports 18 approved therapies and is present in most U.S. cell therapy trials. This isn’t just about adding new products. It’s about locking in steady, high-margin consumables revenue and expanding Repligen’s global reach.
Deal structure and financial outlook
The deal, first announced in July 2026, gave each eligible BioLife shareholder $11.25 in cash and 0.1442 shares of Repligen stock for every BioLife share. Fractional shares were paid out in cash. The payment mix was about 64% Repligen stock and 36% cash, according to an RTT News report. Repligen expects the deal to add at least $0.05 to adjusted earnings per share in the first year, and $0.25 in the second year after closing.
Olivier Loeillot, Repligen’s president and CEO, called out the deal’s impact: “BioLife’s highly differentiated portfolio of products expands our presence in the rapidly growing cell therapy market. [This adds] a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow. [We will] help advance the development and commercialization of next-generation therapies.”
Teams from both companies spent months working out the integration. Repligen’s headquarters stay in Waltham, Massachusetts, but its manufacturing now stretches across the U.S., Estonia, Germany, Ireland, the Netherlands, and Sweden. BioLife’s customer base in Asia Pacific now folds into Repligen’s network, giving the company a stronger international footprint.
The merger was executed in two stages: first, Repligen's Bravo Merger Sub I merged with BioLife, followed by BioLife merging with Bravo Merger Sub II, which became a direct subsidiary of Repligen.
What this means for cell therapy
This isn’t just another buyout. The cell and gene therapy market is hungry for reliable supply chains and specialized tools, as seen in recent reports on new cell therapy storage methods. By bringing in BioLife’s lineup, Repligen can now serve therapy developers at every stage, from early trials to full-scale manufacturing.
Repligen is making its intentions clear: it wants to lead the cell therapy tools market by owning both the technology and the consumables that drive today’s cell therapy production. With a bigger manufacturing base and a wider customer network, Repligen is setting a new standard for what it means to be a full-service supplier in this space. For those watching the industry, this marks a major step up in the race to supply the next wave of cell and gene therapies. In biotech, scale and tight integration often decide who comes out on top.
